AI-generated research brief — verify at source
Lianhua Qingke Tablets Significantly Improve Symptom Resolution in Children With Mycoplasma Pneumonia
In a randomized, placebo-controlled trial, children with mild Mycoplasma pneumoniae pneumonia who received Lianhua Qingke (LHQK) tablets alongside conventional therapy achieved a substantially higher major symptom resolution rate by Day 7 compared to those receiving conventional therapy alone (85.9% vs. 65.6%, p < 0.05). The finding supports LHQK as a potentially useful adjunctive agent, though the trial's modest size and restriction to mild disease warrant measured interpretation.
What Was Studied
The trial investigated whether Lianhua Qingke tablets, a Traditional Chinese Medicine (TCM) formulation, could enhance outcomes when added to standard treatment for children with mild Mycoplasma pneumoniae pneumonia. The primary outcome was the rate of major symptom resolution by Day 7, with secondary attention to cough relief, expectoration, time to recovery, and safety — a clinically meaningful question given that macrolide antibiotic resistance is complicating the standard management of this common pediatric respiratory infection.
How It Was Studied
This was a prospective, randomized, double-blind, placebo-controlled trial conducted across 13 hospitals over a four-month enrollment period, registered in the Chinese Clinical Trial Registry. A total of 160 children aged 4 to 14 years with mild MPP were allocated in a 1:1 ratio to receive either conventional therapy plus LHQK tablets or conventional therapy plus placebo for seven days. The efficacy analysis was performed on a reduced subset of 128 participants who had centrally confirmed Mycoplasma pneumoniae infection, while safety data were collected for all 160 enrolled children. Baseline characteristics were comparable between groups, and medication compliance reached 98.8% in both arms.
What Was Observed
- Major symptom resolution was substantially higher in the LHQK group: By Day 7, 85.9% of children receiving LHQK achieved resolution of major symptoms, compared with 65.6% in the placebo group — a difference of approximately 20 percentage points that reached statistical significance (p < 0.05). This represents the trial's primary endpoint and its most robust finding.
- Cough and expectoration relief rates were also significantly improved: Both cough relief and expectoration relief rates favored the LHQK group, each reaching statistical significance (all p < 0.05), suggesting a specific benefit in respiratory symptom burden beyond the composite primary outcome.
- Time to symptom resolution showed a numerical but non-significant trend: Median time to major symptom resolution was 4.5 days in the LHQK group versus 5.0 days in the placebo group, a half-day difference that did not reach statistical significance (p = 0.072), meaning this result should be treated as preliminary.
- The safety profile appeared favorable: Adverse event incidence was lower in the LHQK group than in the placebo group (2.5% vs. 8.8%), though this difference was not statistically significant (p > 0.05) and no serious adverse events were reported in either arm.
Why This Matters
Mycoplasma pneumoniae is described in this study as a major cause of community-acquired pneumonia in children, and increasing macrolide resistance is explicitly identified as a complicating factor in its treatment. A well-tolerated adjunctive therapy that demonstrably improves symptom resolution rates could have practical relevance in settings where antibiotic options are constrained. The trial’s multicenter design and double-blind methodology strengthen the credibility of the primary symptom resolution finding.
How to Read This Result
While the primary outcome reached statistical significance and the direction of findings is consistently positive, the efficacy analysis rested on only 128 of 160 enrolled participants, the time-to-resolution endpoint did not achieve significance, and the trial was confined to mild disease in a single-country setting — factors that collectively support a cautiously optimistic rather than definitive interpretation of LHQK’s adjunctive benefit.
Limitations
The efficacy analysis was restricted to 128 of the 160 enrolled children — those with centrally confirmed MP infection — reducing statistical power and introducing a potential selection effect. The secondary endpoint of time to symptom resolution fell short of significance (p = 0.072), limiting conclusions about speed of recovery. Enrollment occurred over only four months and included only mild MPP cases, meaning findings cannot be extrapolated to children with moderate or severe disease. The single-country, hospital-based design may also limit generalizability to other clinical environments or patient populations.